Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CARA
- Price
- -
- Stock movement up
- +2.29 (14.34%)
- Company name
- Cara Therapeutic
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 27.82M
- Ent value
- 41.38M
- Price/Sales
- 3.20
- Price/Book
- 39.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 434.49
- PEG
- -
- EPS growth
- 1.20%
- 1 year return (CAGR)
- -28.60%
- 3 year return (CAGR)
- -66.35%
- 5 year return (CAGR)
- -48.63%
- 10 year return (CAGR)
- -26.44%
Last updated: 2025-09-12
DIVIDENDS
CARA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.20 |
| Price to Book | 39.35 |
| EV to Sales | 4.76 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.52M |
| EPS (TTM) | -62.70 |
| FCF per share (TTM) | -50.77 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 8.69M |
| Gross profit (TTM) | 7.33M |
| Operating income (TTM) | -82.07M |
| Net income (TTM) | -95.53M |
| EPS (TTM) | -62.70 |
| EPS (1y forward) | 0.04 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 84.43% |
| Operating margin (TTM) | -944.90% |
| Profit margin (TTM) | -1099.76% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 37.06M |
| Net receivables | 1.37M |
| Total current assets | 47.91M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 3.42M |
| Total assets | 51.33M |
| Accounts payable | 2.54M |
| Short/Current long term debt | 3.42M |
| Total current liabilities | 10.04M |
| Total liabilities | 50.62M |
| Shareholder's equity | 707.00K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -74.24M |
| Capital expenditures (TTM) | 3.10M |
| Free cash flow (TTM) | -77.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -13511.32% |
| Return on Assets | -186.10% |
| Return on Invested Capital | -2316.32% |
| Cash Return on Invested Capital | -1875.41% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| CARA | S&P500 | |
| Current price drop from All-time high | -98.26% | -14.24% |
| Highest price drop | -99.17% | -19.00% |
| Date of highest drop | 18 Jun 2024 | 8 Apr 2025 |
| Avg drop from high | -54.79% | -2.49% |
| Avg time to new high | 148 days | 6 days |
| Max time to new high | 1011 days | 89 days |
COMPANY DETAILS
Marketcap
27.82M
Marketcap category
Small-cap
Description
Cara Therapeutics, Inc. operates as a biopharmaceutical company that focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Employees
10
Investor relations
SEC filings
CEO
Derek Chalmers
Country
USA
City
Stamford
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner